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Background: Genetic predisposition to breast cancer (BC) has been extensively explored to achieve an enhanced understanding 
of the biology of BC. Targeting candidate genes to screen different genetic variants such as RAD51 gene that plays a critical role 
in DNA repair pathways including the double-strand break repair system is an important task. Aim: To study several single nucleotide 
polymorphisms (SNPs) within RAD51-UTR gene and to find their relationship with BC risk and prognosis among Jordanian females. 
Materials and Methods: In this case-control study, DNA sequencing technique was used to screen SNPs within the untranslated 
region (UTR) of RAD51 in 206 cases and 185 controls and the resulting data were statistically analyzed using different types of ge-
netic analyses. Patients’ clinical and pathological features were obtained from their medical records to perform genotype-phenotype 
association analysis. Results: Our findings show a significant association between both SNPs rs528590644, rs1801320 and BC risk 
(p = 0.016). We estimated the correlation between many of BC prognostic factors and BC risk, and we found an association be-
tween rs1801321 and age at first menstruation (p = 0.032) in addition to a strong correlation between age at BC diagnosis and 
rs1801320 (p = 0.008). Conclusion: RAD51-UTR polymorphisms may be involved in BC development and progression.
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Breast cancer �BC� is a m�ltifactorial disease as-
sociated with several factors responsible for its devel-
opment and progression s�ch as smoking� oxidative 
stress� pregnancy stat�s� radiation expos�re� behavior� 
diet� and stress [�]. A combination of these environ-
mental and patient-related factors can ca�se DNA 
damage and genomic alterations� which may lead 
to BC development �s�ally when the DNA repair system 
is altered. Homologo�s recombination �HR� proteins 
play a cr�cial role in maintaining DNA integrity �nder 
many environmental genotoxic factors [�� �]. Genetic 
impairments within critical genes that play a specific 
role in carcinogenesis-related f�nctions may infl�ence 
BC development or progression. DNA repairing path-
ways are the foremost defense mechanisms against 
genomic instability and DNA damage [�]. Fail�re of DNA 
repair system may shift the cell fate to cancer develop-
ment rather proceeding to apoptosis. For instance� 
m�tations in BRCA1 and BRCA2 are associated with 
BC occ�rrence in aro�nd ��% of total cases. There-
fore� alterations in other DNA repairing proteins have 
been proposed to be associated with the development 
of many cancers incl�ding BC. M�tations� in partic�lar� 
single n�cleotide polymorphisms �SNPs� are the most 
investigated genetic variants in the h�man genome 
to seek a clear vision of the correlation between these 
variants and malignancies incl�ding BC [�� 6].
DNA do�ble-strand breaks �DSBs� occ�r nat�rally 
d�ring cell division or may be ca�sed by environmental 
expos�re [7]. DSB repair mechanism is a f�ndamental 
process to maintain the genome integrity and to detect 
the DSBs that lead to promoting carcinogenesis [8� 
�]. Exposing genes that are involved in HR pathway 
of DSBs repair to the field of st�dy may provide �n-
derstanding for the biology of cancer [��]. Variants 
within different genes incl�ding ATM� BRIP1� CHEK2, 
and XRCC2 have been identified as BC inherited risk 
genetic variants [�����].
Also� RAD51 has been recently in the spotlight 
as a key protein that plays a critical role in HR by medi-
ating the synopsis of the two homologo�s strands [���
�6]. RAD51 gene is located on ��q��.� and comprises 
nine coding exons [�7]; any change in the genetic 
components of this gene co�ld lead to a significant 
alteration in the expressed proteins� which may affect 
the DSBs repair pathway [�8].
rs�8����� is a significant variant located in � �n-
translated region ��UTR� of the RAD51 gene and in-
volves the s�bstit�tion of G to C at position ���. It has 
been s�ggested that this polymorphism manip�lates 
mRNA stability of RAD51 which in t�rn affects the 
DNA repair pathway and s�bseq�ently ind�ces t�mor 
formation [��]. In addition to rs�8������ the con-
trib�tion of RAD51 polymorphisms to BC has been 
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explored [��]. Many epidemiological st�dies investi-
gated the role of RAD51 in BC development and pro-
gression [�7� ��� ��]. Interestingly� these st�dies have 
shown disparities in the findings� possibly d�e to the 
heterogeneity of the st�died cohorts [��� ����6].
The p�rpose of this st�dy is to investigate the 
correlation between SNPs within the �-UTR region 
within RAD51 gene and BC risk. F�rthermore� we aim 
to clarify the association between a gro�p of clinico-
pathological feat�res of BC and the screened poly-
morphisms in RAD51.
MATERIALS AND METHODS
Study cohort. In this st�dy� ��6 female BC pa-
tients in addition to �8� matched healthy individ�als 
were recr�ited as st�dy s�bjects from the �ordanian 
Royal Medical Services hospital. All the participants 
were randomly selected from �ordanian Arab descent. 
Ethical approval was obtained from the Int�itional Re-
view Board at �ordan University of Science and Tech-
nology with the ethical code n�mber ���/���/���7�. 
Written informed consents were obtained for each 
vol�nteer. Descriptive data abo�t patients incl�ding 
demographic� clinical� and pathological information 
were collected from patients’ medical records at �or-
danian Royal Medical Services.
DNA extraction. Blood sample �� ml� was with-
drawn from each participant and DNA was extracted 
�sing the DNA P�rification KitWizard® Genomic �Pro-
mega� USA�. The extracted DNA was then tested for 
q�ality and q�antity validation �sing gel electrophore-
sis and Nano-Drop ND-���� UV-Vis Spectrophotom-
eter �BioDrop� UK�.
PCR and DNA sequencing. Polymerase chain 
reaction �PCR� was performed to amplify the �-UTR 
within RAD51 gene �sing specific sets of primers; 
F -�-AGCTGGGAACTGCAACTCAT-� and R-�-
CGCCTCACACACTCACCTC-� [�7]. Briefly� � µL of the 
extracted genomic DNA pl�s � µL of primers were 
added to ��.� µL of �X ready to �se PCR master mix 
from New England Biolabs �Taq �X Master Mix� USA� 
with n�clease-free water to reach the vol�me of �� µL.
The DNA seq�encing was performed as previo�sly 
p�blished by Al-Eitan et al. [�8] �sing the genetic 
analyzer �����x�� Applied Biosystems� USA� accord-
ing to the BigDyeTerminator v�.� Cycle Seq�encing 
Kit �Applied Biosystems� USA�. S�bseq�ently� the 
chromatograms of the seq�enced DNA were vis�-
alized �sing Chromas Pro software v.� �USA� and 
compared to a reference seq�ence �Ensembl ID: 
ENSG������78�68� �sing Ensembl genome browser 
�http://www.ensembl.org/index. html�.
Statistical analysis. Hardy — Weinberg eq�ilib-
ri�m eq�ation �Co�rt lab — HW calc�lator� was �sed 
to calc�late the genotypic and allelic freq�encies. 
The genetic association was estimated �sing Pear-
son’s chi-sq�are test. In addition� genetic association 
�sing different genetic models was performed �sing 
SNPSTAT software �version �.�� of Biocond�ctor�. 
Pearson’s chi-sq�are and ANOVA tests were also 
�sed to estimate the phenotype-genotype correla-
tion. In this st�dy� p-val�e was considered as statisti-
cally significant only if less than �.��. The Statistical 
Package for the Social Sciences �SPSS�� version 
��.� �SPSS� Inc.� USA� was �sed to cond�ct the sta-
tistical analysis.
RESULTS
Candidate SNPs of RAD51 and their associa-
tion with BC. Table � ill�strates the selected poly-
morphisms within RAD51-UTR. In this st�dy� fo�r 
o�t of the seven SNPs that have been screened were 
polymorphic. The genotype and allele freq�encies for 
the screened polymorphisms of RAD51 are also s�m-
marized in Table �. Remarkably� the variant allele �C� 
of rs��8���6�� was not detected among patients� 
while it acco�nted for �% among controls and the 
minor allele �G� of rs���8�6��� was not observed 
among controls except for individ�al cases. F�rther-
more� the homozygo�s variant allele �TT� distrib�tion 
among cases ��6.�%� was significantly higher than 
among controls ���.�%� of rs�8�����. O�r findings 
revealed that both polymorphisms rs��8���6�� and 
rs�8����� were associated with BC with the same p-
val�e �p = �.��6�. However� neither rs���8�6��� nor 
rs�8����� were in correlation with BC in this st�dy 
�Table ��.
In addition� a genetic association test �sing dif-
ferent genetic models was performed to clarify 
the relationship between RAD51 polymorphisms 
and BC. As Table � shows� only rs�8����� and 
rs�8����� were applicable for this test. O�r findings 
revealed that none of the investigated models showed 
significant association with BC except for the co-domi-
nant and recessive models of rs�8����� �p = �.��� and 
�.���8� respectively� �Table ��.
Haplotype analysis. Haplotypes res�lted from 
RAD51-UTR polymorphisms �rs�8������ rs�8������ 
rs���8�6���� and rs��8���6��� are demonstrated 
in Table �. The table shows haplotype variant freq�en-
cies in case and control. The haplotype analysis in this 
st�dy revealed a significant association between GTCA 
haplotype and BC risk� p = �.��� �Table ��.
Genotype-phenotype analysis. In this st�dy 
gro�p of clinical and pathological feat�res of BC being 
characterized and tested for correlation with RAD51-
UTR polymorphisms� most of these feat�res are 
prognostic and predictive factors for BC. Table � il-
l�strates these parameters and their association 
with RAD51 SNPs. We fo�nd an association between 
rs�8����� and age at first menstr�ation �p = �.����� 
in addition to a strong correlation between age 
at BC diagnosis and rs�8����� �p = �.��8�. However� 
there was no relationship between rs���8�6��� and 
any of the investigated clinical factors �Table ��.
Moreover� Table � s�mmarizes the pathologi-
cal parameters of BC and their relationship with 
RAD51-UTR variants. Common and critical factors 
for BC prognosis s�ch as progesterone �PR� and 
estrogen receptor �ER� stat�s and h�man epithelial 
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receptor � �HER�� were incl�ded. In this c�rrent st�dy� 
no association was disclosed between any of these 
pathological factors and the investigated polymor-
phisms of RAD51-UTR.
The heterogeneity of molec�lar markers �PR� ER� 
and HER�� which are known as imm�nohistochemistry 
�IHC� profile was also st�died. Considering that data 
was available for only ��� patients� Table � shows three 
different types of BC according to IHC profiles: l�minal 
A; ER�+� and /or PR�+� pl�s HER���� l�minal B: ER�+� 
and /or PR�+� pl�s HER�+� and T.N: triple negative 
ER��� and PR��� pl�s HER���. However� we did not 
Table 1. Genetic association between RAD51-UTR candidate SNPs and BC













































































Table 2. Genetic association between RAD51-UTR polymorphisms and BC using different genetic models
Gene SNP ID Category test p-value*
RAD51-UTR
rs1801320 Co-dominant: common Hz (GG) vs Het (GT) vs Rare Hz(TT)
Dominant; Common Hz (GG) vs Het and Rare Hz (GT+TT)
Recessive: Common Hz and Het (GG+GT) vs Rare Hz (TT)





rs1801321 Co-dominant: common Hz (GG) vs Het (GC) vs Rare Hz(CC)
Dominant; Common Hz (GG) vs Het and Rare Hz (GC+CC)
Recessive: Common Hz and Het (GG+GC) vs Rare Hz (CC)






Table 3. Haplotype analysis of RAD51-UTR polymorphisms
Haplotype RAD51-UTR (rs1801321, rs1801320, 
rs530836900 and rs528590644) Frequency of block
Frequency ratio (case: con-
trol), % Odd ratio (95%) CI p-value
GGCA 0.4462 0.3976: 0.5021 1.0 NA
GTCA 0.4184 0.4641: 0.3659 0.65 (0.48–0.88) 0.0058*
CGCA 0.1215 0.1333: 0.1069 0.63 (0.39–1.03) 0.067
Global haplotype association p-value: 0.0067
Note:*significant difference.
Table 4. Association of RAD51-UTR SNPs with clinicopathological characteristics of BC patients
Clinical characteristics
rs1801321
(GG vs CG vs CC)
p-value
rs1801320





Body mass index** 0.621 0.848 0.408
First pregnancy (age)** 0.910 0.579 0.520
Age at BC diagnosis** 0.645 0.008*** 0.487
Allergy* 0.498 0.501 0.098
Age at first menstruation** 0.032*** 0.722 0.516
Breastfeeding status* 0.375 0.833 0.473
Age at menopause** 0.261 0.837 0.476
Family history* 0.169 0.577 0.482
Co-morbidity* 0.910 0.335 0.291
Smoking* 0.653 0.512 0.533
Pathological characteristics
Progesterone receptor* 0.884 0.051 0.311
Estrogen receptor* 0.923 0.240 0.587
HER2* 0.964 0.499 0.986
IHC profile (L.A vs L.B vs T.N) 0.931 0.413 NA
Tumor differentiation grade* 0.871 0.083 0.461
Axillary lymph nodes* 0.245 0.143 0.306
Tumor stage* 0.860 0.509 0.770
Histology classification* 0.669 0.906 0.370
Tumor size** 0.236 0.919 0.402
Lymph node involvement* 0.298 0.694 0.646
Note: *genotype-phenotype association p-value using Pearson Chi-squared test; **genotype-phenotype association p-value using ANOVA test. L.A: lumi-
nal A; L.B: luminal B; T.N: triple negative; ***significant difference.
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detect any association between BC types and RAD51-
UTR polymorphisms �Table ��.
DISCUSSION
A malf�nction in DNA repair mechanics is the start-
ing point for cancer development [��]. DSB is a reli-
able repair system responsible for genome integrity 
and stability [��]. Correspondingly� genetic alteration 
within a f�nctional gene that plays a key role in DSB 
repair pathway may lead to cancer development in-
cl�ding BC [��]. RAD51 is one of the important genes 
that participate in the DSB repair system [�����].
In this st�dy� fo�r polymorphic SNPs have been 
screened in BC female patients and matched healthy 
s�bjects. We investigated the association between 
RAD5�-UTR polymorphisms and BC as well as the 
clinical and pathological prognosis parameters.
Genetic association analyses in this st�dy in-
dicated a significant association between both 
polymorphisms �rs��8���6��� rs�8������ and 
BC risk while the other two SNPs were not in cor-
relation with BC. O�r findings showed that the dis-
trib�tion of rs��8���6�� variant allele �C� was only 
distrib�ted among controls b�t not among cases 
in contrast to the common allele �A� distrib�tion. 
In light of these res�lts� we propose the �A� allele 
of rs��8���6�� within RAD51-UTR as an increased 
risk variant for BC among �ordanian females. Con-
cerning rs�8������ we s�ggest that both variant 
allele �T� and homozygo�s variant �TT� genotype 
are implicated in BC development and progression 
in �ordanian women. Haplotype analysis was con-
d�cted in this st�dy to show the combined effects 
of RAD51-UTR on BC risk. Significantly� we propose 
that GTCA haplotype is linked with BC s�sceptibility.
F�rthermore� the infl�ence of RAD51-UTR 
polymorphisms on BC prognosis was explored. 
In this work� we detect an association between 
rs�8����� and age at first menstr�ation in addi-
tion to a correlation between age at BC diagno-
sis and rs�8�����. Therefore� we propose that 
RAD51 variants may interfere with BC prognosis. 
However� we did not find any connection between 
RAD51 polymorphisms and the investigated patho-
logical factors.
Several st�dies investigated candidate poly-
morphisms within the RAD51 gene and how they 
co�ld be correlated to BC development and pro-
gression [��� �6��8]. However� inconsistent find-
ings among ethnic gro�ps and within the same 
pop�lation have been revealed. In accordance 
to this st�dy� Sekhar et al. [��] stated that homozy-
go�s s�bstit�tion �CC� of ��� G > C polymorphism 
within RAD51 increases the risk of BC significantly. 
In contrast� Korak et al. [��]� Sliwinski et al. [��]� 
and Synoweic et al. [��] did not find any association 
between BC risk and RAD51 ���G > C polymorphism. 
Le Calvez-Kelm et al. [�6] also screened RAD51 for 
rare variants in �.��� early-onset BC cases in ad-
dition to �.��� controls and reported no significant 
disease-related genetic variant.
Despite the independent role of RAD51 in t�mori-
genesis� it has been known to interact with other genes 
s�ch as BRCA�/� for HR repair. In this regard� the im-
pact of RAD51 variants among BC BRCA�/� m�tation 
carriers on BC risk has been also explored� both st�d-
ies by Lose et al. [�7] and Rapakko et al. [��] reported 
no association between BRCA1 and BRCA2-negative 
BC and RAD51 variation. Nevertheless� RAD�� has 




Figure. A representative chromatogram of the �’UTR region in the RAD51 gene: а — representing sample with GG genotype for 
G���C variant and GT genotype for G�7�T variant; b — representing sample with GC genotype for G���C variant and GG genotype 
for the G�7�T variant; c — representing sample with GG genotype for the G���C variant and TT genotype for the G�7�T variant
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tastasis [��� ��]. And RAD�� targeting have shown 
a promising BC treatment option [��� ��].
In concl�sion� we propose that genetic altera-
tion of RAD51 may infl�ence its vital f�nction and 
correspondingly infl�ence t�mor formation incl�d-
ing BC. Moreover� RAD51 polymorphisms may 
be involved in poor prognosis of BC. Comprehensive 
st�dies incl�ding protein and mRNA research are 
needed to reveal the precise role of RAD51 rare vari-
ants on BC progression and development for better 
�nderstanding of BC biology that may lead to new 
therape�tic regimens which in t�rn increase the s�r-
vival rates worldwide.
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ГЕНЕТИЧНИЙ ПОЛІМОРФІЗМ ГАПЛОТИПУ 
RAD51-UTR ТА СХИЛЬНІСТЬ ДО РАКУ 
МОЛОЧНОЇ ЗАЛОЗИ У ЖІНОК З ЙОРДАНСЬКОЇ 
ПОПУЛЯЦІЇ
М.С. Аль Зубі1, *, Л.Н. Аль-Ейтан2, Д.М. Рабаба1, К. Аль-
Бетейнех1, Р. Фарзанд3, Г.Е. Квін4, М.М. Тамбувала4, Х.А. 
Бакші4, *
1Університет Ярмука, Ірбід 21163, Йорданія
2Йорданський університет науки і технологій, 
Ірбід 22110, Йорданія
3Університет Хаддерсфілда, Квінсгейт, HD12ZD, 
Сполучене Королівство
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Сполучене Королівство
Стан питання: Генетична схильність до раку молочної 
залози �РМЗ� широко вивчалася для досягнення більш 
глибокого розуміння біології РМЗ. Пошук генів-кандида-
тів для скринінгу різних генетичних варіантів� таких як ген 
RAD51� який відіграє важливу роль у репарації ДНК� вклю-
чаючи систему репарації дволанцюгових розривів� є важ-
ливим завданням. Мета: Дослідити кілька однонуклео-
тидних поліморфізмів �SNP� у гені RAD51-UTR і виявити їх 
взаємозв’язок з ризиком розвитку РМЗ і прогнозом серед 
йорданських жінок. Матеріали та методи. У цьому до-
слідженні «випадок-контроль» метод секвенування ДНК 
використовувався для скринінгу SNP в нетрансльованій 
ділянці �UTR� RAD�� у ��6 випадках і �8� контрольних 
зразках. Отримані дані були статистично проаналізовані 
з використанням різних методів генетичного аналізу. Ін-
формація про клінічні та патологічні характеристики паці-
єнтів була отримана з їх медичних карт і використана для 
проведення аналізу асоціації генотип-фенотип. Резуль-
тати: Отримані результати вказують на значний зв’язок 
між обома SNP rs��8���6��� rs�8����� і ризиком роз-
витку РМЗ �p = ����6�. Ми оцінили кореляцію між багать-
ма прогностичними факторами РМЗ і ризиком РМЗ і ви-
явили зв’язок між rs�8����� і віком першої менструації 
�p = ������� а також сильну кореляцію між віком на момент 
встановлення  діагнозу і rs�8����� �p = ����8�. Висновок: 
Поліморфізми RAD51-UTR можуть відігравати роль у роз-
витку та прогресії РМЗ.
Ключові слова: рак молочної залози� RAD51-UTR� про-
гноз� шляхи репарації ДНК.
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